Why a wakefulness drug is pharma’s latest obsession

Pharmaceutical companies are increasingly focused on orexin therapies, which target the wakefulness-promoting neuropeptide orexin, in hopes of developing new psychiatric treatments. These potential drugs aim to address conditions like depression and anxiety by modulating the brain's wakefulness pathways. This scientific advance could revolutionize mental health care, offering more targeted and effective treatments. The significance of this lies in the potential to improve the lives of millions suffering from mental health issues with fewer side effects compared to existing medications.